PA
ITCI

Pinnacle Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Pinnacle Associates’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-135,344
Closed -$17.9M – 864
2025
Q1 		$17.9M Sell
135,344
-9,320
-6% -$1.16M 0.26% 90
2024
Q4 		$12.1M Sell
144,664
-31,460
-18% -$2.59M 0.16% 130
2024
Q3 		$12.6M Buy
176,124
+5,055
+3% +$380K 0.21% 128
2024
Q2 		$11.7M Sell
171,069
-2,823
-2% -$196K 0.18% 131
2024
Q1 		$12M Sell
173,892
-2,232
-1% -$153K 0.19% 134
2023
Q4 		$12.6M Sell
176,124
-1,094
-0.6% -$62.9K 0.21% 129
2023
Q3 		$9.23M Sell
177,218
-7,703
-4% -$449K 0.17% 148
2023
Q2 		$11.7M Sell
184,921
-6,982
-4% -$435K 0.2% 128
2023
Q1 		$10.4M Sell
191,903
-3,154
-2% -$152K 0.21% 133
2022
Q4 		$10.3M Sell
195,057
-3,385
-2% -$170K 0.22% 127
2022
Q3 		$9.23M Sell
198,442
-7,583
-4% -$396K 0.21% 138
2022
Q2 		$11.8M Sell
206,025
-509
-0.2% -$28.9K 0.26% 119
2022
Q1 		$12.6M Sell
206,534
-9,987
-5% -$519K 0.22% 127
2021
Q4 		$11.3M Sell
216,521
-1,367
-0.6% -$57.4K 0.2% 136
2021
Q3 		$8.12M Sell
217,888
-7,610
-3% -$265K 0.15% 161
2021
Q2 		$9.21M Buy
225,498
+2,829
+1% +$105K 0.17% 150
2021
Q1 		$7.55M Sell
222,669
-24,525
-10% -$851K 0.14% 159
2020
Q4 		$7.86M Sell
247,194
-16,986
-6% -$446K 0.16% 142
2020
Q3 		$6.78M Sell
264,180
-11,595
-4% -$265K 0.16% 151
2020
Q2 		$7.08M Buy
+275,775
New +$5.58M 0.17% 141

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pinnacle Associates's ITCI Position: Q2 2025 in Review

Pinnacle Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 135,344 shares — an estimated $17.9M sold.

Pinnacle Associates first reported a position in ITCI in Q2 2020 and held it in 20 quarters. The position peaked at $17.9M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Pinnacle Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Pinnacle Associates sold 135,344 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $17.9M.
  • Pinnacle Associates first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 20 quarters.
  • Pinnacle Associates's Intra-Cellular Therapies Inc. position peaked at $17.9M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Pinnacle Associates's 13F filing for Q2 2025, filed 4 Aug 2025.